 | | Vol. 14.24 – 8 July, 2022 |
| |
|
|
| Researchers integrated high-throughput and high-content techniques to investigate the tumor cell and immunological response signatures to different treatment regimens.
[Nature Biotechnology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors used an IL-17A fate reporter mouse and an MHC-II tetramer to analyze antigen-specific CD4+ T cell subsets and isolate them for single-cell RNA sequencing after oral immunization with cholera toxin and ovalbumin.
[Science Immunology] |
|
|
|
| Investigators used mRNAs to encode a half-life-extended human IL-2 mutein with mutations promoting reliance on IL-2Rα.
[Nature Communications] |
|
|
|
| Researchers developed a multimeric T cell identifying reagent platform using 2D DNA origami scaffolds to spatially organize peptide-MHCs (pMHCs) with nanoscale control.
[Nature Communications] |
|
|
|
| The authors reported how the signature cytokine of follicular helper T cells, IL-21, acted as a key regulator of the initial B cell response by accelerating cell cycle progression and the rate of cycle entry, increasing their contribution to the ensuing germinal cancer.
[EMBO Reports] |
|
|
|
| Investigators tested the hypothesis that bispecific T cell engagers could activate and redirect cytotoxic T lymphocytes to increase the anti-tumor effect of oncolytic adenoviruses.
[Oncoimmunology] |
|
|
|
| Scientists evaluated IL-23 and IL-23R expression, as well as changes in the asthmatic phenotype in mice administered particulate matter and a low dose of house dust mite.
[Journal of Cellular and Molecular Medicine] |
|
|
|
| Researchers investigated the relationship between immune surveillance mechanisms and periodontitis in cancer patients.
[Scientific Reports] |
|
|
|
| The authors showed that the mice exposed to microcystin-LR had an altered microbiome signature that harbored antibiotic resistance genes.
[Scientific Reports] |
|  |
|
|
|
| Scientists review what is known regarding age-associated B cells development and distribution during diseases including systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis.
[Cellular and Molecular Life Sciences] |
|
|
|
|
| Horizon Therapeutics plc announced that the FDA has approved the supplemental Biologics License Application expanding the labeling to include KRYSTEXXA® injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy.
[Horizon Therapeutics plc] |
|
|
|
| Alvotech announced the initiation of the company’s confirmatory clinical study for AVT06, a biosimilar candidate to Eylea®.
[Alvotech] |
|
|
|
|
| October 9 – 13, 2022
Cairns, Australia |
|
|
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
